Houman David Hemmati

Opinion author

Houman David Hemmati is a physician, scientist and rare disease advocate who has worked in clinical medicine, biomedical research and the development of novel therapies for patients with serious and life-threatening conditions. He is currently a medical advisor or board member of several biotherapeutics companies.

Opinion

FDA must ensure American patients can access new and experimental drugs

The FDA has taken important steps through Operation TrialBlazer and stronger scrutiny of foreign clinical data, but more must be done to make the United States more competitive in attracting clinical trials as China’s capabilities rise.

October 5, 2026

7 min read

Houman David Hemmati

A sick businessman works on hospital bed with a saline solution medical drip bag in office meeting room. Boss, employee, patient, work hard, overwork, project, illness, tired, and workaholic concept

Opinion

The FDA needs a patient-first vision—and adcomms with patients at the table

FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.

July 13, 2026

4 min read

Houman David Hemmati